LUCAS (Lucentis Compared to Avastin Study)

NCT01127360 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

420

Enrollment

OTHER

Sponsor class

Conditions

Exudative Age-related Macular Degeneration

Interventions

DRUG: Bevacizumab
DRUG: Ranibizumab

Sponsor

Oslo University Hospital